C:
C:
5. Derivative Liability
During 2012, in relation to the reverse Merger and the three offerings under the Private Placement, the Company issued 21,347,182
five-year warrants to purchase the Company’s common stock. In October and November of 2011, the Company issued 1,500,000 five-year warrants in connection with Convertible Notes. The exercise price of the warrants is protected against
down-round financing throughout the term of the warrant, as described below. Pursuant to ASC 815-15 and ASC 815-40, the fair value of the warrants of approximately $32.7 million and $1.3 million in 2012 and 2011, respectively, was recorded as a
derivative liability on the issuance dates.
The Company revalued the warrants as of the end of each reporting period, and the estimated fair
value of the outstanding warrant liabilities was $6.9 million, $20.6 million and $1.3 million as of March 31, 2013, December 31, 2012 and December 31, 2011, respectively. The changes in fair value of the derivative liabilities
for the three months ended March 31, 2013 and 2012, and the years ended December 31, 2012 and 2011 were increases of $12.0 million, $13.5 million, $9.9 million and less than $0.1 million, respectively, and are included in other income
(expense) in the statements of operations.
During the three months ended March 31, 2013 and the year ended December 31, 2012,
6,990,556 and 13,010,237 warrants that were classified as derivative liabilities were exercised. The warrants were revalued as of the settlement date, and the change in fair value was recognized to earnings. In addition, in 2013 the Company entered
into amendment agreements with certain of the warrant holders, which removed the down-round pricing protection provision, resulting in 600,065 of these warrants being reclassified from liability instruments to equity instruments. The Company also recognized a reduction in the warrant liability
based on the fair value as of the settlement date for the warrants exercised and as of the modification date for the warrants that were amended, with a corresponding increase in additional paid-in capital.
The derivative liabilities were valued at the closing dates of the Private Placement and the end of each reporting period using a Monte Carlo valuation
model with the following assumptions:
C:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2011 |
|
|
December 31, 2012 |
|
|
March 31, 2013 |
|
C:
C:
Closing price per share of common stock
|
|
$ |
N/A |
|
|
$ |
2.60 |
|
|
$ |
3.68 |
|
Exercise price per share
|
|
$ |
1.00 |
|
|
$ |
1.00 |
|
|
$ |
1.00 |
|
Expected volatility
|
|
|
109.8 |
% |
|
|
92.9 |
% |
|
|
88.8 |
% |
Risk-free interest rate
|
|
|
0.83 |
% |
|
|
0.54 |
% |
|
|
0.57 |
% |
Dividend yield
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Remaining expected term of underlying securities (years)
|
|
|
5.00 |
|
|
|
4.16 |
|
|
|
3.88 |
|
C:
In addition, as of the valuation dates, management assessed the probabilities of future financings assumptions in the Monte Carlo
valuation models. Management also applied a discount for lack of marketability to the valuation of the derivative liabilities based on such trading restrictions due to certain of the shares not being registered.
In accordance with the terms of the warrant agreements, if, prior to the expiration date of the warrants, the Company issues additional shares of common
stock, as defined below, without consideration or for a consideration per share less than the exercise price of the warrants in effect immediately prior to such issue, then the exercise price shall be reduced, concurrently with such issue, to a
price (calculated to the nearest cent) determined by multiplying such exercise price by a fraction, (A) the numerator of which shall be (1) the number of shares of common stock outstanding immediately prior to such issue plus (2) the
number of shares of common stock which the aggregate consideration received or to be received by the Company for the total number of additional shares of common stock so issued would purchase at such exercise price; and (B) the denominator of
which shall be the number of shares of common stock outstanding immediately prior to such issue plus the number of such additional shares of common stock so issued; provided that (i) all shares of common stock issuable upon conversion or
exchange of convertible securities outstanding immediately prior to such issue shall be deemed to be outstanding, and (ii) the number of shares of common stock deemed issuable upon conversion or exchange of such outstanding convertible
securities shall be determined without giving effect to any adjustments to the conversion or exchange price or conversion or exchange rate of such convertible securities resulting from the issuance of additional shares of common stock that is the
subject of this calculation. For purposes of the warrants, “additional shares of common stock” shall mean all shares of common stock issued by the Company after the effective date (including without limitation any shares of common stock
issuable upon conversion or exchange of any convertible securities or upon exercise of any option or warrant, on an as-converted basis), other than: (i) shares of common stock (and/or warrants for any class of equity securities of the Company)
issued or issuable upon conversion or exchange of any convertible securities or exercise of any options or warrants outstanding on the effective date; (ii) shares of common stock issued or issuable by reason of a dividend, stock split, split-up
or other distribution on shares of common stock; (iii) shares of common stock (or options with respect thereto) issued or issuable to employees or directors of, or consultants to, the Company or any of its subsidiaries pursuant to a plan,
agreement or arrangement approved by the Board of Directors of the Company; (iv) any securities issued or issuable by the Company pursuant to (A) the Private Placement; or (B) the Merger; (v) securities issued pursuant to
acquisitions or strategic transactions approved by a majority of disinterested directors of the Company, provided that any such issuance shall only be to a person which is, itself or through its subsidiaries, an operating company in a business
synergistic with the business of the Company and in which the Company receives benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising
capital or to an entity whose primary business is investing in securities and (vi) securities issued to financial institutions, institutional investors or lessors in connection with credit arrangements, equipment financings or similar
transactions approved by a majority of disinterested directors of the Company, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is
investing in securities.
Upon each adjustment of the exercise price pursuant to the provisions stated above, the number of warrant shares
issuable upon exercise of the warrants shall be adjusted by multiplying a number equal to the exercise price in effect immediately prior to such adjustment by the number of warrant shares issuable upon exercise of the warrant immediately prior to
such adjustment and dividing the product so obtained by the adjusted exercise price.
|